Navigation Links
Abt Bio-Pharma Solutions, Inc. Names Nandini Hadker as Executive Director, Succeeding Susan Windham-Bannister
Date:7/9/2008

LEXINGTON, Mass., July 9 /PRNewswire/ -- Abt Bio-Pharma Solutions, Inc. (ABS), a global provider of integrated clinical, health economic, and strategic commercialization solutions, is pleased to announce that Nandini Hadker, an expert in marketing and business strategy, has been promoted to Executive Director and will oversee ABS' strategic commercialization practice, succeeding Susan Windham-Bannister, who has been appointed President & CEO of the Massachusetts Life Sciences Center (MLSC).

Dr. Windham-Bannister has worked with many biopharma companies and other health products/service providers during her more than 30 years with ABS and Abt Associates. The capabilities and relationships developed during her years with Abt Associates make Dr. Windham-Bannister uniquely qualified to guide the Center's implementation of Governor Deval Patrick's plan to secure Massachusetts' position as a global leader in life sciences research and development.

"With [the Massachusetts Life Sciences] initiative we take our rightful place as a global leader in the life sciences," said Governor Patrick. "There is no place in the world with as great a concentration of life sciences talent, resources and vision as Massachusetts. With these resources -- and the collaboration and support of the industry, academia, business and government -- we are on our way to helping find new cures for diseases, creating new jobs, and positioning ourselves for long-term economic growth."

Ms. Hadker has worked closely with Dr. Windham-Bannister on the company's many high-profile engagements with Fortune 50 clients, advising them on new product development, pricing and brand management. In addition to methodological expertise, Ms. Hadker combines multi-industry expertise and business acumen to help clients identify, assess and quantify opportunities, navigate complex marketplaces, and successfully position themselves with their customers -- be they physicians, hospitals, patients or payors. Ms. Hadker has played a critical role in the development of the company's strategic commercialization practice and is also active as a member of the company's senior management team.

"We are delighted that Sue's knowledge of and commitment to the life sciences industry has been recognized in this manner, and expect her to make a great contribution to Governor Patrick's initiative," said Steven Fosburg, President of ABS. "Although we are sorry to lose her as a colleague, as members of the Massachusetts life sciences community we look forward to seeing the benefits of her efforts for many years to come. Here at ABS, we anticipate a seamless transition as Nandini takes over sole leadership of our commercial strategy practice. We expect great things from her, as the group is poised for significant growth in the coming year and Nandini is the right candidate to lead that effort."

Ms. Hadker holds a Masters in Economics from Boston University and her work has been published in numerous peer-reviewed, scientific healthcare journals including The Journal of Occupational and Environmental Medicine and Haemophelia. She has also been a featured speaker at many professional conferences, especially in the area of new product planning and pharmaceutical pricing.

The ABS team has provided integrated strategic, research, and communications services to the pharmaceutical, biotechnology, medical device, and diagnostics industries for more than 20 years. The company specializes in demonstrating the value, safety, and efficacy of health technologies through prospective studies such as registries and clinical trials as well as through analyses of retrospective data. ABS teams of senior, seasoned staff help sponsors develop their research agendas, successfully conduct their research programs, communicate the results in peer-reviewed journals, and, where appropriate, appear before regulatory authorities. Primary service offerings include registries and other late-phase clinical studies, marketing research and strategy, health economics and outcomes research, and biometrics. Previously known as Abt Associates Clinical Trials, the company was renamed Abt Bio-Pharma Solutions and established as a wholly owned subsidiary of Abt Associates in April 2008.


'/>"/>
SOURCE Abt Bio-Pharma Solutions, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
2. Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services
3. Huifeng Bio-Pharmaceutical (HFGB) Provides Update on Current Business and COS Certification
4. Bio-Pharma Industry Experts Deliver M&A Value Through Integration Excellence
5. Huifeng Bio-Pharmaceutical (HFGB) Announces No Earthquake Related Damage to Facilities
6. Huifeng Bio-Pharmaceutical (HFGB) to Release First Quarter 2008 Earnings Results on May 15, 2008
7. Leading Overseas Scientists Establish High-Tech Bio-Pharmaceutical Enterprise in Changzhou
8. Abt Associates Clinical Trials Announces Name Change to Abt Bio-Pharma Solutions, Inc.
9. Huifeng Bio-Pharmaceutical (HFGB) Announces 2007 Full Year Results
10. Skystar Bio-Pharmaceutical Raises 2007 Revenue Guidance to $15.8 Million
11. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... Prussia, PA (PRWEB) , ... February 09, 2016 , ... ... Development, Europe. Based in Paris, he will focus on acquiring new accounts and ... being met. , “Fred brings to our European clients more than ...
(Date:2/9/2016)... CA (PRWEB) , ... February 09, 2016 , ... ... strategic changes over the years and Open Access publishing is one of the ... With its 700+ open access journals and 3000+ International Conferences ...
(Date:2/9/2016)... Feb. 9, 2016  DNAtrix, a clinical ... cancer, announced that its lead product, DNX-2401, ... as an orphan medicinal product for the ... of glioma, strikes approximately 25,000 people a ... http://photos.prnewswire.com/prnh/20160208/330986LOGO --> ...
(Date:2/9/2016)... and LONDON , February 9, 2016 /PRNewswire/ ... tech replace paper and protect IP   ... laboratory notebook (ELN) will be rolled out in ... and development (R&D) and protect valuable IP. Users will be ... a specific researcher or experiment as part of the application, ...
Breaking Biology Technology:
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
(Date:1/13/2016)... 2016 --> ... market report titled - Biometric Sensors Market - Global Industry ... 2023. According to the report, the global biometric sensors market was valued ... reach US$1,625.8 mn by 2023, expanding at a CAGR ... volume, the biometric sensors market is expected to reach ...
(Date:1/8/2016)... and MANCHESTER, United Kingdom , Jan. 8, ... of innovative sensor-based diagnostic products, today announced the closing of ... and existing investors.  Proceeds from the financing will be used ... a hand-held device for detecting early-stage pressure ulcers. ... after receiving CE Mark approval. The device,s introduction ...
Breaking Biology News(10 mins):